Sarepta's Q4: A Beat on Revenue, But a Reset on ELEVIDYS

The immediate event is a stark divergence between top-line and bottom-line results. Sarepta's fourth-quarter report showed a clear revenue beat but a severe earnings miss, creating a classic "good news, bad news" setup for investors. The core issue is a temporary disruption to its flagship gene therapy, ELEVIDYS.

On the surface, the numbers are mixed. Total revenue of $442.9 million topped estimates, but the adjusted loss per share of $3.58 was far worse than the expected $0.77 loss. The primary drag was ELEVIDYS, which generated only $110.4 million in Q4. Management directly tied this shortfall to a severe flu season and the rescheduling of six infusions into 2026. This represents a significant hit to the business, as the therapy's net product revenue for the full year 2025 was $898.7 million.

The resilience came from the company's other franchise. The PMO exon-skipping therapies, often seen as cannibalizing ELEVIDYS, remained stable at $259.2 million in Q4. This stability is crucial, providing a cash flow anchor while the ELEVIDYS business resets. It shows the underlying demand for Sarepta's DMD treatments remains intact, even as the gene therapy faces a temporary setback.

The bottom line was crushed by a $193 million inventory and supply charge, including a $165 million reserve for excess ELEVIDYS and PMO inventory. This accounting hit, combined with the lower ELEVIDYS sales, explains the wide earnings miss. The event-driven setup here is clear: a revenue beat masks a fundamental operational hiccup, and the severe earnings miss reflects both the sales disruption and the costs of managing it.

The ELEVIDYS Reset: Commercial and Clinical Mechanics

The event-driven narrative for ELEVIDYS is now one of deliberate reset and clinical validation. Management has explicitly labeled 2026 as a "critical reset year" for the therapy, following a turbulent 2025. The immediate commercial mechanics are clear: a severe flu season and the rescheduling of six planned infusions into 2026 caused a sharp Q4 sales drop to $110.4 million. The company's new guidance reflects this reset, projecting 2026 approved-therapy revenue of roughly $1.2 billion to $1.4 billion, with the CEO noting first-quarter revenue could be "about flat to perhaps down 15%" from the prior quarter.

The core of the reset is a successful transition to a traditional label for ambulatory patients. Executives cited an updated label, expanded outreach, and early signs of renewed site engagement as key to addressing the "information imbalance" that plagued the therapy last year. The company is now pushing beyond treatment centers to reach referring physicians and caregivers, emphasizing longer-term outcomes like muscle MRI findings. While these efforts show early "green shoots," the impact will be delayed by the therapy's long enrollment-to-infusion cycle, meaning any revenue recovery is likely to be gradual.

Clinically, the reset is anchored by robust three-year data. The EMBARK study's top-line results showed a statistically significant 4.39-point NSAA benefit versus external controls, with treated patients showing a 73% slowing of disease progression by Time to Rise and a 70% slowing by 10 Meter Walk/Run. This durability data is critical for rebuilding confidence and supporting the therapy's label.

The immediate pipeline catalyst is a sirolimus pretreatment Cohort 8 in non-ambulatory patients, which is now underway. Data from this cohort is expected by the end of 2026, providing a near-term clinical milestone that could further expand the therapy's addressable population. For now, the setup is one of a business in a deliberate, multi-faceted reset-commercially re-engaging, clinically validating, and clinically advancing-with the full impact still months away.

Financial Impact and Valuation Setup

The event-driven setup now hinges on cash flow and the buffer it provides. Sarepta ended 2025 with a solid $954 million in cash, a position that grew by $89 million in the quarter. This liquidity is the critical financial buffer for the ELEVIDYS reset. It funds the company through the commercial transition and clinical pipeline investment without immediate dilution risk, strengthening the capital structure after the removal of a debt overhang via refinancing.

The near-term risk/reward is defined by the guidance and its implied trajectory. Management guided 2026 net product revenue to a range of $1.2 billion to $1.4 billion, with a clear directive to "model toward the low end of the range at least for the time being." This caution is warranted by the Q4 shortfall and the expectation that first-quarter revenue could be "about flat to perhaps down 15%" from the prior quarter. The base business, driven by the stable PMO franchise, generated over $330 million in positive cash flow in 2025, excluding Arrowhead payments. The company expects to deliver operating profit and positive cash flow in 2026, though unit-volume margins are expected to settle in the high 70% range as production volumes decrease.

The bottom line is a trade-off between a strong cash position and a reset revenue path. The $954 million war chest provides runway, but the guidance implies a significant drop from the 2025 net product revenue of $1.86 billion. For investors, the immediate catalyst is the execution of the reset. The risk is that the commercial recovery is slower than anticipated, testing the cash buffer. The reward is a stabilized, diversified franchise with a validated gene therapy and a pipeline advancing, all on a stronger balance sheet. The event has shifted the focus from a single-therapy valuation to a multi-year cash flow story.

Catalysts and Risks: What to Watch Next

The reset thesis now hinges on a handful of near-term events. The key commercial catalyst is the first tangible sign of renewed site engagement and patient enrollment in the first half of 2026. Management has pointed to early "green shoots," like enrollment forms from dormant sites, but the therapy's long cycle from enrollment to infusion means any revenue recovery will be gradual. Investors must watch for data on site activity and new patient starts to confirm the commercial re-engagement is gaining real traction.

A major operational risk is the CEO transition. Doug Ingram plans to retire around the end of 2026, and the board has launched a comprehensive successor search. While the company is executing a reset, a leadership change so close to the expected revenue recovery phase introduces an element of uncertainty. The stability of the commercial and clinical strategy during this transition will be a watchpoint.

On the pipeline front, two regulatory catalysts are in play. The company is in confirmatory discussions with the FDA for two PMO exon-skipping therapies, and any updates on these pathways could provide a near-term boost to the stable franchise. More immediately, the sirolimus pretreatment Cohort 8 in non-ambulatory patients is underway, with data expected by the end of 2026. This cohort is critical for expanding ELEVIDYS' addressable population, and its progress will be a key clinical milestone to monitor.